-
20m 17sPart 2 | Session 4 TRILUMINATE Pivotal Trial: Lessons Learned from Tricuspid TEER
-
10m 9sPart 2 | Session 5 Real-World EVOQUE Outcomes from TVT Registry
-
8m 6sPart 2 | Session 6 PASCAL Precision System in Complex Degenerative MR
-
7m 2sPart 2 | Session 7 PREVUE-VALVE: Prevalence of Valvular Heart Disease in Older Americans
-
7m 4s
-
6m 55sPart 2 | Session 9 Short-CUT: Lithotripsy Vs Cutting Balloon for CAD
-
4m 10sPart 2 | Session 10 10-Year Mortality in NOBLE: PCI vs CABG for Left Main Disease
-
28m 2sPart 2 | Session 11 1-Year ENCIRCLE TMVR Results with SAPIEN M3
-
10m 32s
-
14m 58s
-
6m 49sPart 1 | Session 1 5 Trials That Will Change My Practice with Dr Mirvat Alasnag
-
2m 12sPart 1 | Session 2 2 Trials That Will Change My Practice with Prof Rasha Al-Lamee
-
3m 51sPart 1 | Session 3 3 Ways AI Will Change Your Practice
-
21m 50sPart 1 | Session 4 TCT 25 Structural Interventions Highlights
-
5m 33sPart 2 | Session 1 SELUTION DeNovo: 1-Year Results Comparing Sirolimus Balloon vs DES in PCI
TCT 2025 - Three-year findings from LIFE-BTK show the Esprit™ BTK scaffold is a durable and effective treatment option for patients with CLTI.
Dr Sahil Parikh (Columbia University Vagelos College of Physicians & Surgeons, New York, US) joins us to share the three-year findings from LIFE-BTK (NCT04227899). The randomized controlled trial aimed to evaluate the safety and efficacy of the Esprit™ BTK everolimus-eluting resorbable scaffold compared to percutaneous transluminal angioplasty (PTA) treatment for infrapopliteal lesions.
Findings suggested clinical advantage over PTA across three years of study, with a 33% improvement in the composite endpoint of limb salvage and primary patency, and a 45% reduction in clinically-driven target lesion revascularizaion in favour of the Esprit™ BTK device.
Interview Questions:
- What is the reasoning behind the LIFE-BTK trial?
- Could you tell us about the unique features of the Esprit™ BTK scaffold?
- What was the study design and patient population?
- What were the key three-year findings from the LIFE-BTK trial?
- What do these results mean for practice, and what’s next for follow-up?
Recorded on-site at TCT Conference in San Francisco, 2025.
Editor: Yazmin Sadik
Video Specialist: Tom Green, Mike Knight
Support: This is an independent interview produced by Transcatheter Academy.
Stay Updated with Our TCT 2025 Video Coverage
We’re bringing you independent, critical insights straight from TCT 2025.
Join Prof Nicolas Van Mieghem in Cardiology Conference Perspectives as he discusses what the late-breaking data could mean for your practice.
Don’t miss our short Expert Interviews with investigators, offering concise analyses and practical take-home messages.
Hear Dr Mirvat Alasnag and Dr Rasha Al-Lamee share their views on the data they believe will have the greatest impact on clinical practice.
Follow the hot topics driving innovation in interventional cardiology, and stay tuned for fresh perspectives, real-world insights and global viewpoints, all coming soon on Transcatheter Academy.
More from this programme
Part 1
Highlights
Part 2
Expert Interviews
Part 3
NVM Cardiology Conference Perspectives
A focused video series where Prof Nicolas Van Mieghem offers expert reflections on the most impactful late-breaking trials shaping interventional cardiology at TCT 2025.
Faculty Biographies
Sahil Parikh
Director of Endovascular Services and Assistant Professor of Medicine
Dr Sahil Parikh is Director of Endovascular Services and Assistant Professor of Medicine at Columbia University Vagelos College of Physicians & Surgeons in New York. His research interests include coronary artery disease, peripheral arterial disease including claudication, critical limb ischemia, renovascular disease, cerebrovascular disease, venous medicine and thrombosis.
Dr Parikh has authored over 50 original manuscripts and reviews, and frequently lectures at national meetings, including TCT, ACC and SCAI.
Comments